PRESS RELEASE
December 14, 2007

Ticker Symbol: CUR

DIAGNOCURE ANNOUNCES FOURTH QUARTER 2007 AND YEAR-END RESULTS

QUEBEC CITY, December 14, 2007— DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering lab services, announced a net loss from continuing operations of $3,320,193 or $0.09 per share for the fourth quarter ending October 31, 2007, and a net loss from continuing operations of $9,156,219 or $0.24 per share for the fiscal year.

These results are substantially in line with management expectations. They reflect the end of the revenue recognition from the continued calendar payments received from Gen-Probe which had been amortized over a 42-month period from the signing of the original license agreement, the activities undertaken during the past year to focus activities in line with Company plans, as well as the on-going commitment to develop and acquire tests for the detection and management of cancer. At the end of the quarter, cash, short-term investments and long-term investments stood at $32,867,526, up from $18,319,194 as at October 31, 2006. This increase of $14,483,332 is attributable to the net proceeds of $23,353,098 from the April 2007 financing.

Highlights of the Quarter

On August 16, 2007, DiagnoCure announced that it had acquired Catalyst Oncology of Worcester, MA, and its lead proprietary prognostic tests based on Shc proteins for breast, colon and potentially other cancers. The terms of the agreement called for an upfront payment of approximately US$3 million comprised of cash and DiagnoCure shares followed by potential future payments related to the achievement of specific milestones.

The acquired tests have been validated in multiple clinical studies involving patients with five tumor types. Results have shown the tests to be strong indicators for a patient's risk of disease recurrence, as well as predictors of response to certain cancer therapies, such as tamoxifen or traditional chemotherapy.

Results for the Fiscal year ended October 31, 2007

Total revenues for 2007 were $3,467,425 compared with $5,033,092 for the same period of 2006. Revenue recognition of the continued calendar payments and research agreement from Gen-Probe was $1,711,940 for the period, down $1,508,795 from the prior year due to the end of the revenue recognition from the continued calendar payments received from Gen-Probe which had been amortized over a 42-month period from the signing of the original license agreement. Royalty revenues from Gen-Probe were $127,843 for 2007 compared with $11,944 for 2006. Sales of DiagnoCure's bladder cancer test, ImmunoCyt™ / uCyt+™, were $352,351 for 2007 versus $378,327 for the same period a year ago. There were no sales of uPM3™ by DiagnoCure in 2007 since DiagnoCure had withdrawn its uPM3™ test from the market in mid-2006 when Gen-Probe began to sell their version of the PCA3 test. Sales of the DiagnoCure developed uPM3™ ASR prostate cancer test for 2006 were $376,660. Also in 2007, DiagnoCure sold less clinical samples to Gen-Probe, for an amount of $80,412 for 2007 compared with $258,418 for 2006, indicating the completion of their R&D testing.

Interest income increased $407,871 to $1,194,879 for 2007 compared with $787,008 for the same period of 2006. The increase is attributable to the net proceeds of $23,353,098 received in April 2007 from the public offering of 5,850,000 common shares at a price of $4.30 each.

Cost of sales decreased by $321,230 from $585,515 for 2006 to $264,285 for 2007. This decrease is related to lower actual product sales, as noted above.

Based on the above, for the year ended October 31, 2007, DiagnoCure recorded a net loss before stock-based compensation and restructuring charges of $6,342,733, compared with $5,159,187 for the same period of 2006, an increase of $1,183,546. The net loss from continuing operations including stock-based compensation and restructuring charges was $9,156,219 or $0.24 per share for 2007, compared with $6,491,586 or $0.19 per share, for the same period of 2006. These

results are in line with Company plans and the on-going commitment to develop and commercialize tests for the detection and management of cancer. Further, the 2007 loss also reflects steps taken to focus the Company's vision on high-value diagnostic tests, by acquiring and in-licensing additional cancer biomarkers and establish a reference laboratory to deliver these tests to the clinical market.

Results for the Fourth Quarter of Fiscal 2007

Total revenues for the fourth quarter of 2007 were $495,844 compared with $1,193,775 for the fourth quarter of 2006. In the fourth quarter of 2007, Diagnocure had no revenue recognition of the continued calendar payments and research agreement from Gen-Probe compared with $818,409 for the fourth quarter of 2006. This decrease reflects the end of the revenue recognition from the continued calendar payments received from Gen-Probe which had been amortized over a 42-month period from the signing of the original license agreement. Royalty revenues from Gen-Probe were $43,787 for the fourth quarter of 2007 compared with $6,480 for the fourth quarter of 2006. Sales of DiagnoCure's bladder cancer test, ImmunoCyt™ / uCyt+™, were down $31,717 to $80,218 for the fourth quarter of 2007 versus $111,935 for the same period a year ago. Also in this quarter, DiagnoCure sold less clinical samples to Gen-Probe, for an amount of $13,911 compared with $61,582 in 2006.

Interest income increased $162,559 to $357,928 for the fourth quarter of 2007 compared with $195,369 for the fourth quarter of 2006. The increase is attributable to the interest generated on the net proceed of $23,353,098 received from the April 2007 financing.

Cost of sales decreased $44,326 from $112,792 for the fourth quarter of 2006 to $68,466 for the fourth quarter of 2007. This decrease is related to lower actual product sales, as noted above, for ImmunoCyt™ / uCyt+™ and clinical samples sales.

Based on the above, for the fourth quarter of 2007, DiagnoCure recorded a net loss from continuing operation of $3,320,193 or $0.09 per share, compared with a loss of $1,718,318, or $0.06 per share, for the fourth quarter of 2006. These results are in line with management expectations.

Financial Data

	Three-months ended October 31		For the years ended October 31	
	2007	2006	**2007**	2006
Sales	**94,129**	173,517	**432,763**	1,013,405
Revenue under research and license agreement	**43,787**	824,889	**1,839,783**	3,232,679
Interest	**357,928**	195,369	**1,194,879**	787,008
Total revenues	**495,844**	1,193,775	**3,467,425**	5,033,092
Cost of sales	**68,466**	112,792	**264,285**	585,515
Gross margin	**427,378**	1,080,983	**3,203,140**	4,447,577
Operating expenses (before stock-based compensation and restructuring charges)	**3,105,854**	2,300,192	**9,545,873**	9,606,764
Net loss from continuing operations (before stock-based compensation and restructuring charges)	**(2,678,476)**	(1,219,209)	**(6,342,733)**	(5,159,187)
Restructuring charges	**350,000**	---	**1,262,685**	---
Stock-based compensation	**291,717**	499,109	**1,550,801**	1,332,399
Net loss from continuing operations	**(3,320,193)**	(1,718,318)	**(9,156,219)**	(6,491,586)
Net loss from discontinued operations	**---**	(389,394)	**---**	(595,044)
Net loss	**(3,320,193)**	(2,107,712)	**(9,156,219)**	(7,086,630)
Diluted net loss per share from continuing operations	**(0.09)**	(0.06)	**(0.24)**	(0.19)
Weighted average number of common shares outstanding	**41,718,463**	34,450,147	**38,422,096**	34,401,548

Consolidated Balance Sheets

	As at October 31	
	2007	2006
Cash, cash equivalents, temporary and long-term investments	**32,867,526**	18,319,194
Total assets	**43,585,440**	21,347,421
Shareholders' equity	**40,191,471**	19,704,640

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering lab services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure is currently preparing to launch the first GC-C-based molecular test for the management of colorectal cancer. In 2003, the Company entered into a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation test for PCA3, DiagnoCure's proprietary genetic marker highly specific to prostate cancer. The test is now available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, and in Europe as the CE-marked PROGENSA™ PCA3 *in vitro* assay. In addition to its own research, the Company intends to acquire or in-license additional promising cancer biomarkers from both academic and commercial institutions. For more information visit www.diagnocure.com.

Forward-looking statements

This release contains forward-looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward-looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein.

Contact: **DiagnoCure Inc.**
John C. Schafer, President and Chief Executive Officer
Paule De Blois, Vice President, Corporate Affairs
(418) 527-6100
communications@diagnocure.com

Jean-Pierre Trudel & Associates
Jean-Pierre Trudel
(514) 347-6111
jp.trudel@videotron.ca